FIBROSCANS in 60 RA pts on #MTX for 5 yrs w/ liver studies. Mean age = 39.5yrs, w/ Dz Dur 8.2 yrs, mean BMI 24.4 & MTX 12.5–25 mg for ~8 yrs (cum dose 6728mg). All had normal AST, ALT, APRI, Abd US; fibroscan score = 170 ((steatosis grade 0). Only 4(6.7 %) had mild, fibrosis https://t.co/OOctcfI1sT

Systematic review of Apremilast in soriasis and Psoriatic Arthritis: 28 RCTs involving 6825 patients. Efficacy ( PASI 75 and ACR 20) observed at APR 30 mg or 20 mg bid (RR > 2) & both doses did not affect CRP levels. GI side effx most common (see figure) https://t.co/YqfaWPvmTm https://t.co/z8PfJqp0CJ

DANFLU-2 RCT of 332 438 elderly (43 881 w/ diabetes) tested high (HD-IIV) vs standard dose SD-IIV) flu vaccine. HD-IIV signif. reduced cardioresp., CV, CHF, influenza, hospitalizations vs SD-IIV, irrespective of DM status. Similar results previously seen in a Canadian RA pop. https://t.co/GGZPThoHrs

QD Clinic: Tophi Tales: Management of Uncontrolled Gout Daric Mueller, PA-C and Andrew Sulich, MD, St. Clair Shores, MI, present this QD Clinic: Tophi Tales: Management of Uncontrolled Gout. This QD Clinic is presented as part of RheumNow's "Mission: APP Partners in Care" https://t.co/7JTbC0223I

GLP-1 Agonist plus IL-17 Inhibition in Obese Psoriatic Arthritis Lilly announced the topline results from its phase 3b "TOGETHER PsA" trial, showing that the combination use of ixekizumab (Taltz) and tirzepatide (Zepbound) was superior to IXE alone, yielding both significant https://t.co/8fOXWULH7w

2025 Rheumatologists, In Memorium In 2025, rheumatology lost many of its most influential clinicians, mentors, and colleagues. This honor roll recognizes those who cared for countless patients, shaped generations of rheumatologists, and left a lasting legacy in our field. As Dr. https://t.co/MMa670vsoH

J&J announced positive topline results from Phase 2b JASMINE study showing the efficacy of of nipocalimab, FcRn blocker that reduces AutoAbs & B cell activity. Study met its 24 wk primary endpoint (SRI-4 response) vs placebo. There were no new safety signals https://t.co/KMseKyGirt

Kick off 2026 with #RheumNowLive—two days of cutting-edge rheumatology, rapid-fire STEP talks, interactive Q&A, and real-world insights with Drs. Jack Cush, Arthur Kavanaugh, and a powerhouse faculty. Register: https://t.co/MVgXnacU5q https://t.co/7ajH7Ry0Uj

Anti-mitochondrial M2 Ab (AMA-M2) in 987 IIM pts-- 55 (6%) were AMA-M2 positive. AMA-M2+ had signif. higher rates of polymyositis (56% vs 23.5%), GGT, alk phos levels, & 3 fold more cardiac involvement (60 vs 13%) (arrhythmias, CHF, pulm HTN (31-56%), but no effect on survival https://t.co/8fQzgRfHr4

Best of 2025: 2025 BSR Guideline for Treatment of Axial Spondyloarthritis The British Society of Rheumatology's 2025 Guidelines for treating axSpa focus on both axial and extra-musculoskeletal issues like uveitis, psoriasis, and IBD. They evaluate the effectiveness and safety of https://t.co/8VNQtP3Izj

UK study of 1846 RA pts starting a b/tsDMARDs, ~30% on steroids & majority (2/3) continued use over the first year of new novel treatment. This suggests these aer either severe RA pts or that we are not vigilant in limiting/weaning/stopping steroids in RA patients - which is it? https://t.co/TrAktincKT